TSX Venture Exchange: NVC
VANCOUVER, Feb. 3, 2014 /CNW/ - Neovasc Inc. (TSXV: NVC) today announced
that a first-in-human implantation of its Tiara™ transcatheter mitral
valve was successfully performed on January 30th by physicians at St. Paul's Hospital in Vancouver, BC. The transapical
procedure resulted in the elimination of mitral regurgitation (MR) and
significantly improved heart function in the patient, without the need
for cardiac bypass support and with no procedural complications.
The implantation was conducted by Dr. Anson Cheung, Professor of Surgery
and Director of Cardiac Transplant, and Dr. John Webb, Director of
Interventional Cardiology, at St. Paul's Hospital. They were supported
by Dr. Stefan Verheye, Senior Interventional Cardiologist at the
Antwerp Cardiovascular Center / ZNA Middelheim, Belgium and Dr. Shmuel
Banai, Medical Director of Neovasc and Director of Interventional
Cardiology at Tel Aviv Medical Center, Israel.
Commenting on the procedure, Dr. Cheung stated, "This 73 year-old male
patient had severe functional mitral regurgitation and was considered
an extremely high risk candidate for conventional valve repair or
replacement surgery. The transapical implantation of the Tiara valve
was completed quickly and without complications. It resulted in a
well-functioning bioprosthetic valve with no significant paravalvular
leak or residual MR."
Dr. Cheung added, "We are very pleased that this first implantation went
so smoothly and that the patient's outcome to date is so positive. His
recovery has been uneventful and we will continue to follow him closely
over the coming months. The ability to implant a prosthetic mitral
heart valve using a transcatheter, minimally-invasive approach instead
of conventional open chest, open heart surgery would provide a
much-needed alternative for the many patients who are considered at
high risk for conventional surgery."
Tiara is a self-expanding mitral bioprosthesis specifically designed to
treat mitral valve regurgitation, a serious and poorly served condition
that requires development of highly specialized devices to address the
complex mitral anatomy. Significant mitral regurgitation can lead to
heart failure and death. Conventional surgical treatments are only
appropriate for about half of the estimated four million MR patients in
the US alone.
Tiara is implanted in the heart using a minimally-invasive,
transcatheter approach and is designed to replace the diseased native
mitral valve without the need for open heart surgery or use of a
cardiac bypass machine.
Neovasc CEO Alexei Marko commented, "This successful first implantation
of a transcatheter mitral valve by the team at St. Paul's Hospital is
an exciting clinical milestone for patients with mitral disease. This
procedure has the potential to provide a safe and effective new
therapeutic option that could improve the health and quality of life of
millions of patients worldwide."
About Neovasc Inc.
Neovasc Inc. is a specialty medical device company that develops,
manufactures and markets products for the rapidly growing global
cardiovascular marketplace. Its products include the Neovasc Reducer™
for the treatment of refractory angina and the Tiara™ transcatheter
mitral value replacement device in development for the treatment of
mitral regurgitation. In addition, Neovasc's advanced biological tissue
products are widely used as key components in a variety of third-party
medical products, such as transcatheter heart valves. For more
information, visit: www.neovasc.com.
Statements contained herein that are not based on historical or current
fact, including without limitation statements containing the words
"anticipates," "believes," "may," "continues," "estimates," "expects,"
and "will" and words of similar import, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Such forward looking statements involve
known and unknown risks, uncertainties and other factors that may cause
the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by
such forward-looking statements. Such factors include, among others,
the following: general economic and business conditions, both
nationally and in the regions in which the Company operates; history of
losses and lack of and uncertainty of revenues, ability to obtain
required financing, receipt of regulatory approval of product
candidates, ability to properly integrate newly acquired businesses,
technology changes; competition; changes in business strategy or
development plans; the ability to attract and retain qualified
personnel; existing governmental regulations and changes in, or the
failure to comply with, governmental regulations; liability and other
claims asserted against the Company; and other factors referenced in
the Company's filings with Canadian securities regulators. Although the
Company believes that expectations conveyed by the forward-looking
statements are reasonable based on the information available to it on
the date such statements were made, no assurances can be given as to
the future results, approvals or achievements. Given these
uncertainties, readers are cautioned not to place undue reliance on
such forward-looking statements. The Company does not assume the
obligation to update any forward-looking statements except as otherwise
required by applicable law.
SOURCE: Neovasc Inc.
For further information:
U.S. media & investor contact:
BLL Partners, LLC